{"entity":{"type":"insider","cik":"0001567160","url":"/insider/0001567160","json_url":"/insider/0001567160.json","name":"Gano Kyle","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":75,"n_filings":49,"first":"2013-09-05","last":"2026-01-20","span_basis":"filed_date"},"name_variants":[{"name":"Gano Kyle","source":"filing","n_filings":49,"first_seen":"2013-09-05","last_seen":"2026-01-20"}],"transactions":[{"id":6076495,"accession":"0001567160-26-000002","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001567160-26-000002","line_url":"/filing/0001567160-26-000002","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":36400.0,"shares_display":"36,400","price_per_share":132.70489282417583,"price_display":"132.70","price_state":"stated","total_value":4830458.0988,"total_display":"4,830,458.10","total_whole":"4,830,458","shares_owned_after":140407.0,"shares_owned_after_display":"140,407","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-16","filed_date":"2026-01-20","scope":"insider","n_lines":2},{"id":4651749,"accession":"0001567160-25-000008","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567160-25-000008","line_url":"/filing/0001567160-25-000008#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300.0,"shares_display":"300","price_per_share":141.97,"price_display":"141.97","price_state":"stated","total_value":42591.0,"total_display":"42,591.00","total_whole":"42,591","shares_owned_after":140407.0,"shares_owned_after_display":"140,407","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-04","filed_date":"2025-11-04","scope":"insider"},{"id":4406720,"accession":"0000914475-25-000063","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000914475-25-000063","line_url":"/filing/0000914475-25-000063","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2558.0,"shares_display":"2,558","price_per_share":116.85224910086005,"price_display":"116.85","price_state":"stated","total_value":298908.0532,"total_display":"298,908.05","total_whole":"298,908","shares_owned_after":138872.0,"shares_owned_after_display":"138,872","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-13","filed_date":"2025-02-14","scope":"insider","n_lines":2},{"id":4026938,"accession":"0000914475-25-000049","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000914475-25-000049","line_url":"/filing/0000914475-25-000049#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":980.0,"shares_display":"980","price_per_share":118.3881,"price_display":"118.39","price_state":"stated","total_value":116020.338,"total_display":"116,020.34","total_whole":"116,020","shares_owned_after":137658.0,"shares_owned_after_display":"137,658","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-10","filed_date":"2025-02-12","scope":"insider"},{"id":4058471,"accession":"0000914475-25-000025","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000914475-25-000025","line_url":"/filing/0000914475-25-000025#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1541.0,"shares_display":"1,541","price_per_share":152.8731,"price_display":"152.87","price_state":"stated","total_value":235577.4471,"total_display":"235,577.45","total_whole":"235,577","shares_owned_after":136778.0,"shares_owned_after_display":"136,778","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-31","filed_date":"2025-02-04","scope":"insider"},{"id":4226900,"accession":"0000914475-25-000004","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000914475-25-000004","line_url":"/filing/0000914475-25-000004","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":65000.0,"shares_display":"65,000","price_per_share":141.5007667446154,"price_display":"141.50","price_state":"stated","total_value":9197549.8384,"total_display":"9,197,549.84","total_whole":"9,197,550","shares_owned_after":135392.0,"shares_owned_after_display":"135,392","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-15","filed_date":"2025-01-17","scope":"insider","n_lines":2},{"id":2107014,"accession":"0000914475-24-000072","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000914475-24-000072","line_url":"/filing/0000914475-24-000072#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1352.0,"shares_display":"1,352","price_per_share":132.8947,"price_display":"132.89","price_state":"stated","total_value":179673.6344,"total_display":"179,673.63","total_whole":"179,674","shares_owned_after":135166.0,"shares_owned_after_display":"135,166","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-13","filed_date":"2024-02-15","scope":"insider"},{"id":2059199,"accession":"0000914475-24-000045","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000914475-24-000045","line_url":"/filing/0000914475-24-000045#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":980.0,"shares_display":"980","price_per_share":134.2032,"price_display":"134.20","price_state":"stated","total_value":131519.136,"total_display":"131,519.14","total_whole":"131,519","shares_owned_after":133952.0,"shares_owned_after_display":"133,952","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-08","filed_date":"2024-02-08","scope":"insider"},{"id":2059198,"accession":"0000914475-24-000045","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000914475-24-000045","line_url":"/filing/0000914475-24-000045#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1600.0,"shares_display":"1,600","price_per_share":142.2013,"price_display":"142.20","price_state":"stated","total_value":227522.08,"total_display":"227,522.08","total_whole":"227,522","shares_owned_after":133072.0,"shares_owned_after_display":"133,072","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-06","filed_date":"2024-02-08","scope":"insider"},{"id":3016421,"accession":"0000914475-24-000027","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000914475-24-000027","line_url":"/filing/0000914475-24-000027#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1541.0,"shares_display":"1,541","price_per_share":140.696,"price_display":"140.70","price_state":"stated","total_value":216812.536,"total_display":"216,812.54","total_whole":"216,813","shares_owned_after":131635.0,"shares_owned_after_display":"131,635","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-31","filed_date":"2024-02-02","scope":"insider"},{"id":2079529,"accession":"0000914475-24-000007","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000914475-24-000007","line_url":"/filing/0000914475-24-000007","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":75000.0,"shares_display":"75,000","price_per_share":131.46925961066665,"price_display":"131.47","price_state":"stated","total_value":9860194.4708,"total_display":"9,860,194.47","total_whole":"9,860,194","shares_owned_after":130250.0,"shares_owned_after_display":"130,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-02","filed_date":"2024-01-04","scope":"insider","n_lines":2},{"id":8155373,"accession":"0001209191-23-047135","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-047135","line_url":"/filing/0001209191-23-047135#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2132.0,"shares_display":"2,132","price_per_share":107.4075,"price_display":"107.41","price_state":"stated","total_value":228992.79,"total_display":"228,992.79","total_whole":"228,993","shares_owned_after":130250.0,"shares_owned_after_display":"130,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-21","filed_date":"2023-08-23","scope":"insider"},{"id":8722503,"accession":"0001209191-23-007910","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-23-007910","line_url":"/filing/0001209191-23-007910#line-4","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":980.0,"shares_display":"980","price_per_share":103.9898,"price_display":"103.99","price_state":"stated","total_value":101910.004,"total_display":"101,910.00","total_whole":"101,910","shares_owned_after":128096.0,"shares_owned_after_display":"128,096","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-08","filed_date":"2023-02-08","scope":"insider"},{"id":8722501,"accession":"0001209191-23-007910","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-007910","line_url":"/filing/0001209191-23-007910","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14424.0,"shares_display":"14,424","price_per_share":102.39755994176373,"price_display":"102.40","price_state":"stated","total_value":1476982.4046,"total_display":"1,476,982.40","total_whole":"1,476,982","shares_owned_after":127216.0,"shares_owned_after_display":"127,216","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-07","filed_date":"2023-02-08","scope":"insider","n_lines":2},{"id":8722498,"accession":"0001209191-23-007910","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-007910","line_url":"/filing/0001209191-23-007910#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1600.0,"shares_display":"1,600","price_per_share":105.6422,"price_display":"105.64","price_state":"stated","total_value":169027.52,"total_display":"169,027.52","total_whole":"169,028","shares_owned_after":114257.0,"shares_owned_after_display":"114,257","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-06","filed_date":"2023-02-08","scope":"insider"},{"id":7809516,"accession":"0001209191-23-006275","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-006275","line_url":"/filing/0001209191-23-006275#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1541.0,"shares_display":"1,541","price_per_share":109.9847,"price_display":"109.98","price_state":"stated","total_value":169486.4227,"total_display":"169,486.42","total_whole":"169,486","shares_owned_after":112820.0,"shares_owned_after_display":"112,820","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-31","filed_date":"2023-02-02","scope":"insider"},{"id":6811864,"accession":"0001209191-22-008207","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-22-008207","line_url":"/filing/0001209191-22-008207#line-5","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":980.0,"shares_display":"980","price_per_share":79.672,"price_display":"79.67","price_state":"stated","total_value":78078.56,"total_display":"78,078.56","total_whole":"78,079","shares_owned_after":111173.0,"shares_owned_after_display":"111,173","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-08","filed_date":"2022-02-09","scope":"insider"},{"id":6811860,"accession":"0001209191-22-008207","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-22-008207","line_url":"/filing/0001209191-22-008207","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5900.0,"shares_display":"5,900","price_per_share":80.77104798305085,"price_display":"80.77","price_state":"stated","total_value":476549.1831,"total_display":"476,549.18","total_whole":"476,549","shares_owned_after":107395.0,"shares_owned_after_display":"107,395","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-07","filed_date":"2022-02-09","scope":"insider","n_lines":4},{"id":6605827,"accession":"0001209191-22-002529","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-002529","line_url":"/filing/0001209191-22-002529#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28266.0,"shares_display":"28,266","price_per_share":85.5003,"price_display":"85.50","price_state":"stated","total_value":2416751.4798,"total_display":"2,416,751.48","total_whole":"2,416,751","shares_owned_after":104984.0,"shares_owned_after_display":"104,984","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-05","filed_date":"2022-01-07","scope":"insider"},{"id":4553627,"accession":"0001209191-21-009134","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-009134","line_url":"/filing/0001209191-21-009134","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3693.0,"shares_display":"3,693","price_per_share":116.84751042512862,"price_display":"116.85","price_state":"stated","total_value":431517.856,"total_display":"431,517.86","total_whole":"431,518","shares_owned_after":104768.0,"shares_owned_after_display":"104,768","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-08","filed_date":"2021-02-09","scope":"insider","n_lines":3},{"id":4553611,"accession":"0001209191-21-009134","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-009134","line_url":"/filing/0001209191-21-009134","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2677.0,"shares_display":"2,677","price_per_share":114.0023555472544,"price_display":"114.00","price_state":"stated","total_value":305184.3058,"total_display":"305,184.31","total_whole":"305,184","shares_owned_after":100439.0,"shares_owned_after_display":"100,439","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-05","filed_date":"2021-02-09","scope":"insider","n_lines":2},{"id":2883955,"accession":"0001209191-20-058543","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-058543","line_url":"/filing/0001209191-20-058543#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2257.0,"shares_display":"2,257","price_per_share":90.7268,"price_display":"90.73","price_state":"stated","total_value":204770.3876,"total_display":"204,770.39","total_whole":"204,770","shares_owned_after":98028.0,"shares_owned_after_display":"98,028","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-12","filed_date":"2020-11-16","scope":"insider"},{"id":2293037,"accession":"0001209191-20-045749","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-045749","line_url":"/filing/0001209191-20-045749#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2257.0,"shares_display":"2,257","price_per_share":118.8682,"price_display":"118.87","price_state":"stated","total_value":268285.5274,"total_display":"268,285.53","total_whole":"268,286","shares_owned_after":95997.0,"shares_owned_after_display":"95,997","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-05","filed_date":"2020-08-07","scope":"insider"},{"id":2965129,"accession":"0001209191-20-026066","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-026066","line_url":"/filing/0001209191-20-026066#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1934.0,"shares_display":"1,934","price_per_share":99.4709,"price_display":"99.47","price_state":"stated","total_value":192376.7206,"total_display":"192,376.72","total_whole":"192,377","shares_owned_after":93967.0,"shares_owned_after_display":"93,967","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-04-24","filed_date":"2020-04-28","scope":"insider"},{"id":3253922,"accession":"0001209191-20-008491","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-008491","line_url":"/filing/0001209191-20-008491#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1623.0,"shares_display":"1,623","price_per_share":103.3335,"price_display":"103.33","price_state":"stated","total_value":167710.2705,"total_display":"167,710.27","total_whole":"167,710","shares_owned_after":91975.0,"shares_owned_after_display":"91,975","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-07","filed_date":"2020-02-11","scope":"insider"},{"id":3037850,"accession":"0001209191-20-007695","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-007695","line_url":"/filing/0001209191-20-007695#line-4","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":101.413,"price_display":"101.41","price_state":"stated","total_value":101413.0,"total_display":"101,413.00","total_whole":"101,413","shares_owned_after":90514.0,"shares_owned_after_display":"90,514","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-06","filed_date":"2020-02-07","scope":"insider"},{"id":3037847,"accession":"0001209191-20-007695","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-007695","line_url":"/filing/0001209191-20-007695","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3690.0,"shares_display":"3,690","price_per_share":103.05202615176152,"price_display":"103.05","price_state":"stated","total_value":380261.9765,"total_display":"380,261.98","total_whole":"380,262","shares_owned_after":89614.0,"shares_owned_after_display":"89,614","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-05","filed_date":"2020-02-07","scope":"insider","n_lines":3},{"id":8485197,"accession":"0001209191-19-008630","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-008630","line_url":"/filing/0001209191-19-008630#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":762.0,"shares_display":"762","price_per_share":83.5599,"price_display":"83.56","price_state":"stated","total_value":63672.6438,"total_display":"63,672.64","total_whole":"63,673","shares_owned_after":85833.0,"shares_owned_after_display":"85,833","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-06","filed_date":"2019-02-08","scope":"insider"},{"id":7836086,"accession":"0001209191-19-007849","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-19-007849","line_url":"/filing/0001209191-19-007849","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2434.0,"shares_display":"2,434","price_per_share":88.11898488085455,"price_display":"88.12","price_state":"stated","total_value":214481.6092,"total_display":"214,481.61","total_whole":"214,482","shares_owned_after":83439.0,"shares_owned_after_display":"83,439","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-05","filed_date":"2019-02-06","scope":"insider","n_lines":3},{"id":7836075,"accession":"0001209191-19-007849","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-007849","line_url":"/filing/0001209191-19-007849#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1375.0,"shares_display":"1,375","price_per_share":88.1355,"price_display":"88.14","price_state":"stated","total_value":121186.3125,"total_display":"121,186.31","total_whole":"121,186","shares_owned_after":80117.0,"shares_owned_after_display":"80,117","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-04","filed_date":"2019-02-06","scope":"insider"},{"id":6905050,"accession":"0001209191-18-045265","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-045265","line_url":"/filing/0001209191-18-045265#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28266.0,"shares_display":"28,266","price_per_share":115.0,"price_display":"115.00","price_state":"stated","total_value":3250590.0,"total_display":"3,250,590.00","total_whole":"3,250,590","shares_owned_after":78742.0,"shares_owned_after_display":"78,742","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-08-01","filed_date":"2018-08-03","scope":"insider"},{"id":6494389,"accession":"0001209191-18-017709","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-017709","line_url":"/filing/0001209191-18-017709#line-2","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23650.0,"shares_display":"23,650","price_per_share":90.0,"price_display":"90.00","price_state":"stated","total_value":2128500.0,"total_display":"2,128,500.00","total_whole":"2,128,500","shares_owned_after":78742.0,"shares_owned_after_display":"78,742","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-05","filed_date":"2018-03-07","scope":"insider"},{"id":6471191,"accession":"0001209191-18-008204","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-008204","line_url":"/filing/0001209191-18-008204","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2046.0,"shares_display":"2,046","price_per_share":83.04687741935484,"price_display":"83.05","price_state":"stated","total_value":169913.9112,"total_display":"169,913.91","total_whole":"169,914","shares_owned_after":76950.0,"shares_owned_after_display":"76,950","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-02-05","filed_date":"2018-02-07","scope":"insider","n_lines":2},{"id":5994479,"accession":"0001209191-18-004237","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-004237","line_url":"/filing/0001209191-18-004237#line-1","is_derivative":false,"issuer_cik":"0000914475","issuer_name":"NEUROCRINE BIOSCIENCES INC","issuer_ticker":"NBIX","issuer_name_source":null,"issuer_url":"/issuer/0000914475","owner_cik":"0001567160","owner_name":"Gano Kyle","owner_display_name":"Gano Kyle","owner_url":"/insider/0001567160","role":"Officer (Chief Business Development Off)","role_mark":"O","role_mark_label":"Officer (Chief Business Development Off)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Development Off","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1625.0,"shares_display":"1,625","price_per_share":79.052,"price_display":"79.05","price_state":"stated","total_value":128459.5,"total_display":"128,459.50","total_whole":"128,460","shares_owned_after":74871.0,"shares_owned_after_display":"74,871","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-01-16","filed_date":"2018-01-18","scope":"insider"}],"collapsed":true,"next_cursor":"2018-01-16|5994479","ledger_fault":false,"count":{"value":75,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":75,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":75},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000914475","name":"NEUROCRINE BIOSCIENCES INC","url":"/issuer/0000914475","role":"Director, Officer (Chief Executive Officer)","n_filings":49,"first_seen":"2013-09-05","last_seen":"2026-01-20"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001567160","retrieved_at":"2026-08-27T07:27:34+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}